Acquiring Company
Seraxis
Acquired Company
Sernova Biotherapeutics
MarylandManufacturingBiotechnologyHealth CareBiotechnologyHealth CareTherapeuticsDescription
Seraxis has entered into a merger agreement with Sernova Biotherapeutics to create BetaNova Biotherapeutics, focusing on treatments for type 1 diabetes. The merger is expected to close in November 2026, pending shareholder approval. The combined company will operate research labs and manufacturing capabilities in Germantown. Both companies aim to enhance treatment options for patients with innovative cell-replacement therapies.
Don't miss Seraxis's next move
Get an email the moment Seraxis makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
M&A Insights
Based on deal dataFrequently asked
Who acquired Sernova Biotherapeutics?
Sernova Biotherapeutics was acquired by Seraxis, based in Maryland. The deal was reported on September 12, 2026. Seraxis is a private biotechnology company launched in 2013. It focuses on developing innovative treatments for diabetes. The company specializes in stem cell-derived pancreatic islet cells and manufacturing operations. Seraxis is privately held and operates in Manufacturing.
When did Seraxis acquire Sernova Biotherapeutics?
Seraxis's acquisition of Sernova Biotherapeutics was reported on September 12, 2026. Seraxis has entered into a merger agreement with Sernova Biotherapeutics to create BetaNova Biotherapeutics, focusing on treatments for type 1 diabetes. The merger is expected to close in November 2026, pending shareholder approval. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Sernova Biotherapeutics do?
Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.